Chromium/biotin treatment of type II diabetes

A biotin-based technology, applied in the field of non-insulin-dependent diabetes, can solve the problem of no therapeutic effect on diabetes

Inactive Publication Date: 2000-11-15
NUTRITION 21 INC
View PDF2 Cites 50 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Supranutritive doses of biotin have no therapeutic effect on diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0014] The present invention encompasses the discovery that administration of chromium, in the form of chromium picolinate, to individuals with type 2 diabetes at the highest RDA amount up to five times that amount, in combination with low or high doses of biotin, caused a significant reduction in blood glucose levels and stabilized blood glucose Level. This reduction was much greater than would be expected with either component administered alone, thus predicting a synergistic effect.

[0015] The synthesis of chromium picolinate is described in US5087623. Chromium tripicolinate and biotin are available from health food stores, drug stores, and other sources. To reduce the need for insulin and / or diabetes medications, and to reduce several important risk factors associated with type II diabetes, it is contemplated that the dose of chromium administered to patients as chromium tripicolinate ranges from about 50 to 100...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method for treating Type II diabetes by administering to an affected individual a combination of chromic tripicolinate and biotin. The two compounds are administered orally or parenterally at in daily dosages which provide between 50 and 1,000 mu g of chromium and between 25 mu g and 200 mg biotin, the amounts of chromium and biotin being selected together to provide a greater than additive effect.

Description

field of invention [0001] The present invention relates to the treatment of adult onset non-insulin dependent (type II) diabetes. More specifically, the present invention relates to the treatment of type II diabetes by the administration of chromium picolinate and biotin. Background of the invention [0002] At least 10 million Americans are known to have diabetes, and many more have the disease undiagnosed. In this disease, known as type II, non-insulin-dependent, or adult-onset (as opposed to juvenile diabetes or type I diabetes), the pancreas usually continues to secrete normal amounts of insulin. However, this insulin is not effective in preventing the symptoms of diabetes, including hyperglycemia, insufficiency of carbohydrate metabolism, glycosuria and decreased insulin sensitivity. If these symptoms are not treated, they often cause serious complications. [0003] The drugs commonly used to manage type 2 diabetes fall into two classes: biguanides and sulfonylureas....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/381A61K31/415A61K31/4188A61K31/44A61K33/24A61P3/10
CPCA61K31/415A61K31/44A61K33/24A61P3/10A61K31/28A61K2300/00
Inventor M·F·麦卡蒂
Owner NUTRITION 21 INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap